Analyzing Anti-PD-1 Therapy Benefits in Lung Cancer
Author Information
Author(s): De Saint Basile Hortense, Elaidi Reza, Maaradji Zineb, Blons Hélène, BenDhiab Rym, Gibault Laure, Fabre Elizabeth, Elkord Eyad
Primary Institution: Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, Paris, France
Hypothesis
Does the benefit of anti-PD-1 monotherapy vary based on genetic alterations diagnosed by NGS in patients with non-small cell lung cancer?
Conclusion
The study found no statistically significant differences in survival based on KRAS or TP53 mutations in patients treated with anti-PD-1 therapy.
Supporting Evidence
- Only 20% of patients respond to immune checkpoint inhibitors.
- 54 patients had KRAS mutations and 56 had TP53 mutations.
- Median progression-free survival was 3.5 months for KRAS-mutated patients.
Takeaway
This study looked at how certain gene changes in lung cancer patients affect their response to a specific treatment, but it didn't find clear answers.
Methodology
This was a monocentric, retrospective study analyzing clinical and molecular data from patients treated with anti-PD-1 monotherapy.
Potential Biases
Selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective with a small sample size and missing data, which may affect the reliability of the results.
Participant Demographics
Median age was 65 years, with 65% male and 90% having adenocarcinoma.
Statistical Information
P-Value
P = 0.46 for progression-free survival and P = 0.72 for overall survival.
Confidence Interval
[95% CI 2.73; 17.24] for PFS and [95% CI 14.1; NA] for OS.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website